Argenx posts first annual profit of over 1 billion dollars
Belgian biotech company argenx has reported its first annual operating profit of more than 1 billion dollars, driven by strong sales of its flagship medicine Vyvgart.
The Ghent-based group saw revenue rise sharply to 4.2 billion in 2025, up from 2.25 billion the year before. Sales of Vyvgart, used to treat autoimmune diseases, increased by 90 per cent.
Operating profit reached 1.1 billion, compared with a small loss a year earlier. Net profit climbed to 1.3 billion. In 2024, net profit was boosted by a one-off tax benefit, making this year’s result more solid and organic.
Vyvgart was first launched in the United States in 2022, followed by Europe and Japan. The drug is now approved for three autoimmune conditions and is also available as a pre-filled syringe that patients can inject themselves. Analysts believe it could become one of the world’s top-selling medicines.
Argenx says growth is set to continue. The company treated 19,000 patients worldwide last year and aims to reach 50,000 patients by 2030. It is also testing Vyvgart for additional diseases, including ocular myasthenia gravis, where early results have been positive.
The company expects further expansion in 2026, supported by a growing pipeline of new treatments in development.
#FlandersNewsService | EU Commissioner for Competition Margrethe Vestager, Ghent mayor Mathias De Clercq and prime minister Alexander De Croo visit argenx in Zwijnaarde, February 2024 © BELGA PHOTO BENOIT DOPPAGNE
Related news
